PH31261A - Methods for inhibiting endometriosis. - Google Patents
Methods for inhibiting endometriosis.Info
- Publication number
- PH31261A PH31261A PH49186A PH49186A PH31261A PH 31261 A PH31261 A PH 31261A PH 49186 A PH49186 A PH 49186A PH 49186 A PH49186 A PH 49186A PH 31261 A PH31261 A PH 31261A
- Authority
- PH
- Philippines
- Prior art keywords
- chem
- methods
- inhibiting endometriosis
- endometriosis
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/138,643 US5461065A (en) | 1993-10-15 | 1993-10-15 | Methods for inhibiting endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH31261A true PH31261A (en) | 1998-06-18 |
Family
ID=22482966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH49186A PH31261A (en) | 1993-10-15 | 1994-10-13 | Methods for inhibiting endometriosis. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US5461065A (de) |
| EP (1) | EP0652005B1 (de) |
| JP (1) | JPH07188014A (de) |
| KR (1) | KR950010893A (de) |
| CN (1) | CN1049335C (de) |
| AT (1) | ATE203404T1 (de) |
| AU (1) | AU677700B2 (de) |
| CA (1) | CA2118092A1 (de) |
| CZ (1) | CZ287246B6 (de) |
| DE (1) | DE69427800T2 (de) |
| DK (1) | DK0652005T3 (de) |
| ES (1) | ES2157957T3 (de) |
| GR (1) | GR3036971T3 (de) |
| HU (1) | HUT71235A (de) |
| IL (1) | IL111284A (de) |
| NO (1) | NO311242B1 (de) |
| NZ (1) | NZ264677A (de) |
| PH (1) | PH31261A (de) |
| PT (1) | PT652005E (de) |
| RU (1) | RU2157203C2 (de) |
| SG (1) | SG43319A1 (de) |
| SI (1) | SI0652005T1 (de) |
| TW (1) | TW296382B (de) |
| UA (1) | UA26930C2 (de) |
| ZA (1) | ZA948029B (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| HUT76854A (en) * | 1994-08-22 | 1997-12-29 | Lilly Co Eli | Use of benzotiophene derivatives for production of pharmaceutical compositions inhibiting primary endometrial hyperplasia |
| US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
| US5554600A (en) * | 1995-01-20 | 1996-09-10 | Eli Lilly And Company | Methods for inhibiting endometriosis |
| EP0747380B1 (de) * | 1995-06-07 | 1998-09-30 | Eli Lilly And Company | Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen |
| KR970002795A (ko) | 1995-10-30 | 1997-01-28 | 모리 하루오 | 네비게이션(navigation)장치 |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| CA2214072C (en) * | 1996-08-29 | 2006-11-14 | Eli Lilly And Company | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods |
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| EP1133996A4 (de) * | 1998-11-26 | 2003-04-02 | Teikoku Hormone Mfg Co Ltd | Medizinische zusammensetzungen zur periodischen verabreichung |
| ATE301129T1 (de) | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
| WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| ES2236536T3 (es) * | 2001-05-22 | 2005-07-16 | Eli Lilly And Company | Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos. |
| EP1395563B1 (de) * | 2001-05-22 | 2006-03-29 | Eli Lilly And Company | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
| CA2489813A1 (en) * | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
| BR112012032189B1 (pt) | 2010-06-16 | 2020-11-03 | Endorecherche, Inc | usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| SE500453C2 (sv) * | 1991-10-07 | 1994-06-27 | Karobio Ab | Ett in vitro förfarande för utvärdering av en substans effekter |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-10-15 US US08/138,643 patent/US5461065A/en not_active Expired - Lifetime
-
1994
- 1994-10-12 UA UA94105917A patent/UA26930C2/uk unknown
- 1994-10-13 NZ NZ264677A patent/NZ264677A/en unknown
- 1994-10-13 NO NO19943879A patent/NO311242B1/no not_active IP Right Cessation
- 1994-10-13 IL IL11128494A patent/IL111284A/xx not_active IP Right Cessation
- 1994-10-13 JP JP6247764A patent/JPH07188014A/ja active Pending
- 1994-10-13 ES ES94307528T patent/ES2157957T3/es not_active Expired - Lifetime
- 1994-10-13 CZ CZ19942537A patent/CZ287246B6/cs not_active IP Right Cessation
- 1994-10-13 TW TW083109467A patent/TW296382B/zh active
- 1994-10-13 AT AT94307528T patent/ATE203404T1/de not_active IP Right Cessation
- 1994-10-13 ZA ZA948029A patent/ZA948029B/xx unknown
- 1994-10-13 EP EP94307528A patent/EP0652005B1/de not_active Expired - Lifetime
- 1994-10-13 HU HU9402959A patent/HUT71235A/hu unknown
- 1994-10-13 CA CA002118092A patent/CA2118092A1/en not_active Abandoned
- 1994-10-13 SG SG1996008246A patent/SG43319A1/en unknown
- 1994-10-13 PT PT94307528T patent/PT652005E/pt unknown
- 1994-10-13 AU AU75787/94A patent/AU677700B2/en not_active Ceased
- 1994-10-13 CN CN94117125A patent/CN1049335C/zh not_active Expired - Fee Related
- 1994-10-13 RU RU94036772/14A patent/RU2157203C2/ru active
- 1994-10-13 PH PH49186A patent/PH31261A/en unknown
- 1994-10-13 DE DE69427800T patent/DE69427800T2/de not_active Expired - Fee Related
- 1994-10-13 KR KR1019940026164A patent/KR950010893A/ko not_active Application Discontinuation
- 1994-10-13 SI SI9430388T patent/SI0652005T1/xx unknown
- 1994-10-13 DK DK94307528T patent/DK0652005T3/da active
-
1995
- 1995-04-14 US US08/422,387 patent/US5693656A/en not_active Expired - Fee Related
-
2001
- 2001-10-22 GR GR20010401841T patent/GR3036971T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU94036772A (ru) | 1996-08-27 |
| SG43319A1 (en) | 1997-10-17 |
| DK0652005T3 (da) | 2001-09-24 |
| US5693656A (en) | 1997-12-02 |
| HU9402959D0 (en) | 1995-02-28 |
| NZ264677A (en) | 1997-07-27 |
| US5461065A (en) | 1995-10-24 |
| SI0652005T1 (en) | 2001-12-31 |
| DE69427800D1 (de) | 2001-08-30 |
| DE69427800T2 (de) | 2001-12-06 |
| CN1107043A (zh) | 1995-08-23 |
| GR3036971T3 (en) | 2002-01-31 |
| PT652005E (pt) | 2001-11-30 |
| IL111284A (en) | 2000-02-29 |
| AU677700B2 (en) | 1997-05-01 |
| KR950010893A (ko) | 1995-05-15 |
| EP0652005A1 (de) | 1995-05-10 |
| ES2157957T3 (es) | 2001-09-01 |
| CZ253794A3 (en) | 1995-05-17 |
| NO943879D0 (no) | 1994-10-13 |
| UA26930C2 (uk) | 1999-12-29 |
| RU2157203C2 (ru) | 2000-10-10 |
| CN1049335C (zh) | 2000-02-16 |
| CZ287246B6 (en) | 2000-10-11 |
| JPH07188014A (ja) | 1995-07-25 |
| NO311242B1 (no) | 2001-11-05 |
| ZA948029B (en) | 1996-04-15 |
| NO943879L (no) | 1995-04-18 |
| TW296382B (de) | 1997-01-21 |
| HUT71235A (en) | 1995-11-28 |
| ATE203404T1 (de) | 2001-08-15 |
| AU7578794A (en) | 1995-05-04 |
| EP0652005B1 (de) | 2001-07-25 |
| CA2118092A1 (en) | 1995-04-16 |
| IL111284A0 (en) | 1994-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9402959D0 (en) | Methods for inhibiting endometriosis | |
| IL112048A0 (en) | Methods of inhibiting thrombin | |
| IL112042A0 (en) | Methods of inhibiting seborrhea and acne | |
| PH31596A (en) | Methods of inhibiting uteine fibrosis. | |
| ZA948027B (en) | Methods for inhibiting angiogenesis and angiogenic diseases | |
| ZA9410080B (en) | Methods of inhibiting dysfunctional uterine bleeding | |
| ZA948028B (en) | Methods for inhibiting cartilage degradation | |
| HU9403654D0 (en) | Methods of inhibiting ovarian dysgenesis, delayed puberty or sexual infantilism | |
| PH31440A (en) | Method of inhibiting hirsutism and alopecia in women. |